InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (4 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
4
T+90 hit rate
100%
T+90 mean return
+11.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Cox John, Chief Executive Officer. Director active across 3 companies, notably Dyne Therapeutics, Inc.. Cumulatively, 9 disclosures have been logged. Breakdown: 1 buy · 4 sells. Total volume traded: €172k. History available since 4 September 2024. The latest transaction was filed on 13 May 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations9 total
2,683 sharesCommon StockSEC:0001498428-26-000002:0
3,311 shares@ US$18.360.0018% mcap50.0% of flowCommon StockSEC:0001193125-26-223955
3,311 shares@ US$18.360.0018% mcap50.0% of flowCommon StockSEC:0001193125-26-223955:0
4,061 shares@ US$11.8326.2% of flowCommon StockSEC:0000950170-25-035495:0
145,300 shares0Common StockSEC:0000950170-24-134072:0
800 shares@ US$32.5713.6% of flowCommon StockSEC:0000950170-24-103533:0
Ideal exit: 1 Jun 2025 (T+270)
341 sharesCommon StockSEC:0001415889-23-012134:0
4,026 sharesCommon StockSEC:0001127602-16-040239:0
1,324 sharesCommon StockSEC:0001127602-16-040239:1
9 of 9 declarations
About Cox John
John Cox is the CEO and President of Dyne Therapeutics, Inc. He oversees the company's operations and is responsible for implementing growth strategies. With a strong background in the biopharmaceutical sector, he leads efforts to develop innovative therapies. His leadership is essential in positioning Dyne as a key player in the healthcare field.
